Abstract | OBJECTIVE: PATIENTS AND MEASUREMENTS: Forty patients with hyperprolactinemia were treated with quinagolide ( CV 205-502, Norprolac) for 2-72 months (mean 31.6 months). The patient's ages ranged from 12 to 53 years and 90% were female. Seventeen had no radiologic evidence of tumor; 11 had microadenomas; and 12 had macroadenomas. RESULTS: All patients had a reduction of the serum prolactin following quinagolide therapy with normalization in 82% with no tumor, 73% with microadenomas, and 67% with macroadenomas. Fifty-five percent of microadenoma and 75% of macroadenoma patients had a decrease in tumor size when assessed by a blinded reviewer. Ten of 38 female patients became pregnant while taking quinagolide. The dosage of quinagolide ranged from 75 to 400 [mgr]g/day with a median dose of 100[mgr]g/day. A comparison of side effects in a subgroup of 35 patients who had taken bromocriptine prior to quinagolide administration showed a greater than 75% reduction in nausea, vomiting, dizziness, and drowsiness during quinagolide administration. CONCLUSIONS:
|
Authors | P N Schultz, L Ginsberg, I E McCutcheon, N Samaan, M Leavens, R F Gagel |
Journal | Pituitary
(Pituitary)
Vol. 3
Issue 4
Pg. 239-49
(Dec 2000)
ISSN: 1386-341X [Print] United States |
PMID | 11788012
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Aminoquinolines
- Dopamine Agonists
- quinagolide
- Prolactin
|
Topics |
- Adolescent
- Adult
- Aminoquinolines
(administration & dosage, adverse effects, therapeutic use)
- Child
- Dopamine Agonists
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Pituitary Neoplasms
(drug therapy, pathology)
- Prolactin
(blood)
- Prolactinoma
(drug therapy, pathology)
|